Abstract
Idiosyncratic drug-induced liver injury (DILI) can present with autoimmune features, including positive autoantibodies, hypergammaglobulinemia, and lymphoplasmocytic inflammation on liver biopsy. Differentiating between DILI and idiopathic autoimmune hepatitis (iAIH) can be challenging in part because it is often difficult to establish DILI causality. Drug discontinuation is the main treatment of DILI with autoimmune features, though immunosuppression is indicated in certain circumstances, such as DILI with immunoallergic features. This chapter will address how to differentiate between DILI and iAIH and discuss some of the drugs that are most commonly associated with an autoimmune phenotype.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Boberg KM, Aadland E, Jahnsen J, et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33:99–103.
Bjornsson. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther. 2010;32:3–13.
Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52:2065–76.
Weiler-Normann C, Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol. 2011;55:747–9.
deLemos AS, Foureau DM, Jacobs C, et al. Drug-induced liver injury with autoimmune features. Semin Liver Dis. 2014;34:194–204.
Robin MA, Le Roy M, Descatoire V, et al. Plasma membrane cytochrome P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol. 1997;26(Suppl. 1):23–30.
Castiella A, Zapata E, Lucena MI, et al. Drug-induced autoimmune liver disease: a diagnostic dilemma of an increasingly reported disease. World J Hepatol. 2014;6(4):160–8.
Agarwal VK, McHutchison JG, Hoofnagle JH. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol. 2010;8:463–70.
Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56:958–76.
Paiva LA, Wright PJ, Koff RS. Long-term hepatic memory for hypersensitivity to nitrofurantoin. Am J Gastroenterol. 1992;87(7):891–3.
Lucena MI, Kaplowitz N, Hallal H, et al. Recurrent Drug-Induced Liver Injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol. 2011;55:820–7.
Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138:2246–59.
Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: an overview. Semin Arthritis Rheum. 1999;28(6):392–7.
Stricker BH, Blok AP, Claas FH, et al. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology. 1988;8(3):599–606.
Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51:2040–8.
de Boer YS, Kosinski AS, Urban TJ, et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol. 2017;15:103–12.
Hisamochi A, Kage M, Ide T, et al. An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis. J Gastroenterol. 2016;51:597–607.
Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54:931–9.
Kessler WR, Cummings OW, Eckert G, et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol. 2004;2:625–31.
Lohse AW, Chazouilleres O, Dalekos G, Drenth J, Heneghan M, Hofer H, Lammert F, Lenzi M. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015;63(4):971–1004.
Bhagwat AG, Warren RE. Hepatic reaction to nitrofurantoin. Lancet. 1969;2(7634):1369.
Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135:1924–34.
Appleyard S, Saraswati R, Gorard DA. Autoimmune hepatitis triggered by nitrofurantoin: a case series. J Med Case Rep. 2010;4:311.
Ford TJ, Dillon JF. Minocycline hepatitis. Eur J Gastroenterol Hepatol. 2008;8:796–9.
Ramakrishna J, Johnson AR, Banner BF. Long-term minocycline use for acne in healthy adolescents can cause severe autoimmune hepatitis. J Clin Gastroenterol. 2009;43(8):787–90.
Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf. 2000;23(3):197–213.
Russo MW, Hoofnagle JH, Jiezhun G, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology. 2014;60(2):679–86.
Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013;11:558–64.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Schmeltzer, P.A. (2020). Drug-Induced Liver Injury with Autoimmune Features. In: Russo, M. (eds) Diagnosis and Management of Autoimmune Hepatitis. Springer, Cham. https://doi.org/10.1007/978-3-030-33628-8_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-33628-8_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-33627-1
Online ISBN: 978-3-030-33628-8
eBook Packages: MedicineMedicine (R0)